Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.60 |
| ▸ | HTR1A | P08908 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25307357 | 0.84 | SIGMAR1 (0.44) | SIGMAR1HTR1AKDM4ECYP1A2GAA | |
| SCHEMBL7855443 | 0.81 | SIGMAR1 (0.63) | SIGMAR1HTR1AKDM4ECYP1A2GAA | |
| SCHEMBL7521159 | 0.80 | SIGMAR1 (0.66) | SIGMAR1HTR1AKDM4ECYP1A2GAA | |
| SCHEMBL30350966 | 0.80 | SIGMAR1 (0.66) | SIGMAR1HTR1AKDM4ECYP1A2GAA | |
| SCHEMBL7210648 | 0.78 | SIGMAR1 (0.58) | SIGMAR1HTR1AKDM4ECYP1A2GAA | |
| SCHEMBL9765984 | 0.75 | SIGMAR1 (1.00) | SIGMAR1HTR1AKDM4ECYP1A2GAA | |
| SCHEMBL9766026 | 0.75 | SIGMAR1 (1.00) | SIGMAR1HTR1AKDM4ECYP1A2GAA | |
| SCHEMBL13532670 | 0.75 | SIGMAR1 (0.60) | SIGMAR1HTR1AKDM4ECYP1A2GAA | |
| SCHEMBL2615375 | 0.75 | HTR1A (0.61) | SIGMAR1HTR1AKDM4ECYP1A2GAA | |
| SCHEMBL2615376 | 0.75 | HTR1A (0.61) | SIGMAR1HTR1AKDM4ECYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4994460-A | Treatment or prevention of disorders resulting from central nervous system anoxia | BRISTOL-MYERS SQUIBB CO. (US) | 1991-02-19 | — | — | US | disclosed |
| EP-0400661-A1 | Agents for treatment of brain ischemia | Bristol-Myers Squibb Company (US) | 1990-12-05 | — | — | EP | disclosed |